Peptides Unpacked Ep 06: The Functions, Benefits, and Science Behind Growth Hormone Peptides

Growth hormone peptides get marketed like a magic lever for muscle, fat loss, sleep, and longevity, but the real story is messier and far more interesting. I walk you through the five most discussed “growth hormone optimization” therapies and explain what each one is actually trying to do inside the body, from signaling the pituitary to nudging IGF-1 downstream. Along the way, we keep coming back to the core distinction that protects you from hype: changing a lab number is a mechanism, not a guarantee of a better clinical outcome.

We start with CJC-1295 and the GHRH pathway, then unpack why “DAC” matters, how albumin binding extends half-life, and why longer-lasting isn’t automatically better when your body naturally runs on hormone pulses. From there, we move into Ipamorelin and the ghrelin receptor, why clinicians pair it with CJC-1295, and what we still don’t know from long-term randomized human trials. I also explain where Sermorelin fits as a more established, shorter-acting option with a long clinical track record.

Then we talk about the outliers with the biggest misconceptions. Tesamorelin is FDA-approved, but only for a specific condition: excess visceral abdominal fat in HIV-associated lipodystrophy. That approval tells us something real about evidence, and also what it does not prove for general anti-aging. Finally, we break down MK-677 (Ibutamoren), why it’s grouped with peptides even though it isn’t a peptide, what the research suggests about lean body mass and sleep, and why appetite and glucose effects can be deal-breakers for some people. If you want a grounded, evidence-informed way to think about growth hormone peptides, hit subscribe, share the show with a friend, and leave a review so more people can find it.

Transcript

Welcome Back And Series Roadmap

Krista 0:11

Welcome to Serenity and Fire, the podcast where wellness meets grit. I'm your host, Krista Quidenti, founder of fantasy and luxury spot boutique. Join me as we dive into the intriguing world of biohacking, clean living, cutting-edge thought trends, and the possible crime and grit of entrepreneurship. My personal battles with weight management and fertility and the 30-year journey to create and launch my green business, to building a sanctuary for those who have been touched by cancer. I'm here to share real talk, inspire big dreams, and spark a passion for holistic living inside each and every one of you. So let's dive in. Welcome back to Serenity and Fire. Over the last few weeks, we took a little break from our peptide conversation and dove deep into all things skincare. I loved having Kaylee on the show and hope you loved all of the tips, hacks, and information that we shared. Today, I want to jump back into our conversation about peptides and pick up where we left off with growth hormones. If you remember, we spent an entire episode talking about what the growth hormone system actually is. And we did that because I firmly believe that before you can intelligently evaluate a therapy, you have to first understand the system that it's trying to influence. We learned that growth hormone isn't simply a muscle-building hormone. It's part of a remarkably sophisticated communication network involved in repair, recovery, body composition, bone health, collagen production, and much more. We also learned that your body doesn't release growth hormone continuously. It releases it in carefully timed pulses, directed by an intricate conversation between your hypothalamus, your pituitary gland, and several important signaling molecules. Today, we're taking the next step instead of asking how does the system work, we're asking, how are today's therapies trying to influence that system? Which brings us to part six of our peptide series. If you haven't listened to part five of the series, when I introduced growth hormone, I would definitely encourage you to start there because everything we're about to discuss today will make much more sense once you understand how the normal growth hormone system functions. That said, today we're going to explore five of the most commonly discussed therapies in this category. We're talking about CJC 1295, Ipamoralin, SERMORLin, Tesamorlin, and MK677, also known as ibutamorin. Along the way, we'll answer questions like: what does each therapy actually do? Why do physicians choose one over another? Why are some commonly paired together? What is something called DAC and why does it matter? Why is MK677 lumped into this group of peptides if it isn't actually a peptide? And what makes it not a peptide? What does the research show about muscle growth, fat loss, sleep, recovery, and longevity? And of course, where does each therapy land on our promise versus proof scale? By the end of today's episode, my goal is that you'll understand the logic behind why each one of these growth hormone peptides were developed, what biological question each one is trying to answer, and where the science stands today, which is constantly and rapidly changing.

FDA 503A Update And What It Means

Krista 3:25

In fact, before we jump into these peptides, I would be remiss if I didn't mention a major development unfolding and going on in peptide regulation right now. In July, an FDA advisory committee considered several peptides for potential inclusion on what's called the 503A bulks list, including several that we've already discussed: BPC 157, TB500, KPV, Mozzi, CMAX, and Epitolon. Now, I want to be very careful about what that actually means. It's not the same thing as saying that these are FDA approved. It technically isn't an FDA fast track either. And these peptides have not suddenly gone through the traditional drug approval process. What's being considered is something very different, and that is whether qualifying compounding pharmacies may have a lawful pathway to prepare certain formulations using these bulk peptide substances under federal compounding rules. And I find this development really encouraging for a couple of reasons. If some of these peptides ultimately become more accessible through legitimate licensed compounding pharmacies, it could potentially move patients away from questionable gray market sourcing and toward more controlled pharmaceutical channels. Greater legitimate use could also create opportunities for researchers and clinicians to accumulate much larger and real-world data sets and hopefully begin answering some of the questions we've been discussing throughout the series. But, and this is a really big but, access is not evidence. More people taking something doesn't automatically tell us whether it works. Anecdotes aren't clinical trials, and increased availability certainly doesn't answer our biggest questions about long-term safety. So if the FDA ultimately places some of these peptides on the 503A box list, I want to make one thing crystal clear. Again, it does not mean the FDA has approved them as drugs. It does not mean that they've suddenly completed phase one, phase two, and phase three clinical trials. And it does not mean we've answered all of the questions surrounding their long-term safety or effectiveness. It means qualifying compounding pharmacies may now have a lawful pathway to compound that particular bulk substance under specific conditions. And there's another layer to the story that's worth understanding. FDA scientists themselves have raised concerns about some of these peptides, including limited human safety data, peptide impurities, immunogenicity, and questions about how reliably some of these molecules can be characterized. So easier access could be a very positive development, but it also creates the possibility that enthusiasm moves faster than evidence, which means our responsibility as consumers doesn't become smaller. If anything, it probably becomes greater. We need to understand the difference between three very different things: legal access, pharmaceutical quality, and scientific proof. Those terms are not interchangeable, but in the bigger picture, I'm hopeful that greater legitimate scientific and clinical attention to these peptides could eventually help us answer some of the questions we have today. Maybe some of our concerns turn out to be justified, maybe others don't. And maybe some of these therapies eventually prove to be extraordinarily useful. And maybe some ultimately disappoint us. That's exactly what good research is supposed to determine. And I think this development perfectly illustrates something we've been talking about from the very beginning in this whole peptide series, and that's that peptide science and peptide regulation are evolving while we're literally recording this series. So we'll continue following it together.

CJC-1295 And The GHRH Signal

Krista 7:01

Now let's get back to today's conversation and begin with one of the best known peptides in the growth hormone category, CJC1295. If you remember our orchestra analogy, this peptide becomes much easier to understand. We said that the hypothalamus acts as the conductor, the pituitary gland is the orchestra, and the growth hormone-producing cells are like the violin section. The musicians already know how to play, they're simply waiting for the conductor's cue. CJC1295 was designed to influence that cue. More specifically, it was designed to mimic the actions of one of the body's own signaling molecules, GHRH, or growth hormone-releasing hormone. Remember, GHRH is one of the molecules your hypothalamus naturally releases to tell the pituitary, hey, it's time to release growth hormone. CJC1295 binds to those same receptors. So instead of supplying growth hormone directly, it's actually attempting to amplify one of the body's normal signals. And that's an important philosophical difference because the therapy isn't replacing the orchestra, it's trying to encourage the orchestra to perform. But why is that so appealing? Well, because from a biological perspective, if your body already has a carefully regulated system, why bypass it completely? Why not work with it instead? And that was the scientific thinking that drove much of the research into growth hormone secretagogues. Researchers hoped they might stimulate growth hormone release while preserving more of the body's natural feedback systems and pulsatile secretion. Okay, what does all that mean? And why do we care about it? Well, it's because your body regulates hormones for a reason. They're not elevated all day long. Most hormones rise, they fall, they respond to feedback, and then they adjust to what's happening throughout the body. Think about insulin. You wouldn't want insulin to stay elevated 24 hours a day. It rises, it falls. Same thing is true with cortisol and melatonin, and also the same is true with growth hormone. Scientists believe those natural rhythms exist because different tissues respond differently to short bursts versus constant exposure. And they wondered whether working with that natural regulatory system might ultimately prove safer or perhaps even more effective than bypassing it altogether. At this point, we don't really know whether or not that's true, but it explains why so much research shifted towards growth hormone secretagogs in the first place. Think about it. If you inject growth hormone, you're essentially bypassing the body's thermostat. You're deciding when growth hormone will be elevated. If you stimulate the pituitary gland instead, the hope is that the body's own feedback system will still say when enough is enough and shut the system back down when it's appropriate. That's the theory, anyways. Whether that actually translates into better long-term outcomes is still being investigated, but the concept itself is remarkably clever. So does this peptide actually increase growth hormone? And the answer is yes, at least in the short term. Clinical studies have shown that CJC1295 can increase circulating growth hormone levels and subsequently also increase IgF-1. And just to refresh your memory on what IgF-1 is or insulin-like growth factor 1, if you remember from our last peptide episode, growth hormone stimulates IgF-1 production, primarily in the liver, although other tissues can also produce it locally. IgF-1 carries out many of the growth and anabolic effects associated with growth hormone. It participates in cell growth, tissue repair, bone and muscle biology, among other processes. Growth hormone sends the initial signal, but IgF-1 is one of the major molecules that carries that signal forward throughout the body. And if you remember, this is why physicians often watch IGF-1 when they see that these therapies are increasing growth hormone, because IgF-1 gives us a better sense of the downstream activity that we're actually creating. So going back to the clinical studies and how they've shown that CJC 1295 can increase circulating growth hormone levels and subsequently IgF-1, that's exactly what we'd expect based on its mechanism of action. But remember something we've discussed throughout the entire peptide series. Just because we successfully change a laboratory value doesn't automatically mean we've improved someone's health. Those are two different questions. Increasing growth hormone is the mechanism, improving body composition, recovery, or quality of life is the clinical outcome. Good medicine requires us to evaluate both.

DAC, Albumin, And Longer Half-Life

Krista 11:33

So as researchers continued studying CJC 1295, other questions emerged. Could they make the peptide last longer? Could they reduce the number of injections? Could they create a version that remained active in the body for days instead of hours? And that question led to one tiny molecular addition with a surprisingly big impact, DAC. And understanding DAC will teach us something much bigger than just one peptide. It introduces the pharmacology concept of binders, which I'll explain here in just a minute. One of the first things you'll notice when you start researching CJC 1295 is that people often talk about two different versions. One is going to be CJC 1295 with DAC, and one's going to be CJC1295 without DAC. The difference between these two versions comes down to one small molecular addition that impacts the way the peptide's delivered. And what I'm about to teach you is that once again, drug delivery matters, and sometimes how a therapy travels through the body is almost as important as the therapy itself. So what is DAC? It stands for drug affinity complex. It's not another peptide and it's not another medication. It's best thought of as a binder. I know the word binder might be a new concept to some of you, at least in this context, but it's actually a concept you'll encounter quite often throughout medicine. When I use the word binder here, I'm not talking about the kinds of binders that you may have heard about in functional medicine, things like activated charcoal, bentonite clay, or supplements designed to bind toxins in the digestive tract. Those bind substances so they can be eliminated from the body. This kind of binder almost does the opposite. Here, the binder temporarily attaches to the peptide and changes how that molecule behaves inside the body, how long it stays around, how quickly it's broken down, and sometimes how often it needs to be taken. This matters because when natural peptides, which again are tiny protein chains, when those are injected into your body, your enzymes rip them apart or your kidneys flush them out within minutes or hours. So let me break it down into a simpler, more relatable concept. Imagine you're sending an important package across the country. If you simply tape the shipping label directly onto the item, there's a greater chance it gets damaged along the way. Now imagine you place that same item inside a sturdy shipping box or a packaged padded envelope. The contents haven't changed, the destination hasn't changed, the message inside hasn't changed, you've simply given it more protection during the journey. That's very similar to what DAC is doing. It isn't changing what CJC1295 tells your body to do, it's changing how long the peptide can survive the trip. So to understand why DAC works, we need to talk about another important player, and that's a protein called albumin. Albumin is the most abundant protein circulating in your bloodstream. Think of it as one of your body's transportation systems. It carries hormones, fatty acids, certain vitamins, medications, and many other molecules throughout your circulation. When CJC1295 includes DAC, that drug affinity complex allows the peptide to temporarily bind to albumin. In other words, instead of floating through the bloodstream on its own, it's hitching a ride. Albumin protects it from being cleared quite so quickly. And as a result, the peptide remains active in the body much longer. So here's another way to think about it. Imagine you want to cross a river. You could try swimming across by yourself, or you could climb aboard a ferry that's already making the trip. The destination is exactly the same, but the ferry is much more stable, less exhausting, and eliminates the risk of you being swept away and carried downstream, away from your intended destination. Now, molecules obviously aren't actually swimming towards a destination. What DAC is really doing is allowing CJC1295 to bind to albumin and avoid being cleared out of the body as quickly so it remains in circulation much longer. Again, why does any of this really matter? Well, because DAC is bound to albumin, the body treats the peptide like a massive protein molecule instead of a tiny temporary fragment. This protects the peptide from being destroyed and extends its half-life from a few minutes to eight to ten days. This modification allows people using it for research or therapy to dose much less frequently because the growth hormone releasing peptide stays active in the body for days at a time. Same peptide, different delivery strategy. And for those of you who aren't familiar with what half-life means, it simply describes how long it takes for approximately half of the substance to be eliminated from your body. It doesn't mean the therapy suddenly stopped working, it just means its concentration gradually declines over time. So if something has a half-life of eight hours, in eight hours, half of that substance is going to be eliminated from your body. Think about it like lighting a campfire. At first, the flames are roaring, and as time passes, the fire slowly settles into glowing coals. Eventually, only a few embers remain. The fire doesn't disappear all at once, it just gradually loses its intensity. And that's essentially how a half-life works. So the next question naturally becomes this is longer automatically better? And this is one of those questions where the answer isn't simply yes or no. Longer lasting therapies do often mean fewer injections, greater convenience, and more stable drug levels. Those are legitimate advantages, but there can also be potential trade-offs. Remember what we learned in the last peptide episode. Your body normally releases growth hormone impulses, not continuously. Some physicians believe that shorter acting therapies may preserve those natural rhythms more closely. Others prefer longer acting therapies because of convenience or because they believe more sustained stimulation produces better results for certain patients. At this point, though, the scientific community hasn't reached universal agreement on this. And honestly, that's okay because medicine often involves balancing benefits and trade-offs rather than finding one perfect answer for everyone. So, what does the research actually show? The good news is that the biology behind CJC 1295 is very well understood. We know the GHRH pathway exists. We know stimulating that pathway can increase growth hormone release. We also know that increased growth hormone can increase IGF-1, and clinical studies have demonstrated exactly that. Where the question becomes more complicated is determining how much those hormonal changes translate into meaningful improvements in healthy adults over months and years. Do people build more muscle? Do they recover faster, sleep better, lose body fat? Some studies suggest potential benefits. Some physician experiences are absolutely encouraging, but compared with therapies like GLP1 medications, the human evidence remains considerably smaller. And once again, that's not a criticism, it's just simply an honest description of where the science stands today. Changing a laboratory number is the beginning of the conversation, not the end of it. The real question is whether those biological changes translate into meaningful improvements in people's lives. And that's important to keep in mind in this whole entire conversation.

Ipamorelin And The Ghrelin Pathway

Krista 18:40

As researchers continued studying CJC 1295, another interesting observation emerged. Stimulating the GHRH pathway was only half of the conversation. Remember, your body has another important signal involved in growth hormone release, and that's ghrelin, the hunger hormone. That led researchers to ask another question: what if we stimulated both pathways at the same time? And that question brings us to yet another commonly paired peptide in longevity medicine, ipamerelin. So unlike CJC1295, which mimics GHRH, ipamerelin works by activating the ghrelin receptor, sometimes called the growth hormone secretagog receptor or GHSR. In simple terms, it's listening to a different conversation happening inside the body. Think about building a house. You can have several different crews working on the same project, responding to different instructions, but ultimately contributing to the same outcome. CJC 1295 activates the GHRH pathway, essentially sending one signal to the pituitary's growth hormone-producing cells. Ipamarelin activates the ghrelin receptor, sending a second signal through a different pathway. They're not exactly doing the same job. They're two different signaling systems converging on the same construction project, encouraging your pituitary to release growth hormone. That's the biological rationale behind pairing them. The fact that two mechanisms complement each other biologically, however, does not automatically prove that combining the two produces better long-term clinical outcomes. That's a separate question, and the human evidence for these compounded combinations remains limited. From a physiological standpoint, though, the combination makes sense. One peptide stimulates the GHRH pathway, the other stimulates the ghrelin pathway. Together, they may more closely resemble the multiple signals your body naturally uses to regulate growth hormone release. Again, as has been the case with most of the peptides we've discussed, the language I'm using when talking about this peptide is may, not does. That's because while the biological rationale is strong, the long-term clinical evidence is still evolving. Some physicians do report excellent patient outcomes, others remain more cautious. I think both perspectives deserve equal consideration. So that said, you might be asking: does ipamerelin increase hunger? After all, if ipamarelin works through the ghrelin pathway and ghrelin is the hunger hormone, shouldn't people become ravenously hungry? Interestingly, that's not necessarily the case. One of the reasons ipamarelin attracted so much scientific interest is that it appears to stimulate growth hormone release with relatively little effect on appetite compared with some earlier compounds that acted through the same receptor. That doesn't mean appetite changes never occur. Individual responses will, of course, vary, but from a pharmacological standpoint, ipamarelin appears to be more selective than many of its predecessors. And that is the beauty of medicine and scientific discoveries. Researchers are constantly trying to develop new therapies that preserve the desired outfits while minimizing unwanted ones. But what are people hoping to achieve with ipamarelin? When physicians prescribe ipamarelin, often alongside CJC12. 95, the goals frequently include supporting exercise recovery, lean muscle maintenance, body composition, sleep quality, tissue repair, and healthy aging. But remember, those are treatment goals. They're not guaranteed outcomes. Every therapy sounds wonderful when we only talk about what we hope it will do. Science asks a different question, though. What actually has been demonstrated? So, what does the research show with IPAMRelin? The biology is compelling, the mechanism makes sense, several human studies demonstrate increases in growth hormone release. Some studies also show increases in IGF-1. Many physicians practicing regenerative and longevity medicine report positive clinical experiences. But when we step back and ask the highest level scientific question, do we have large long-term randomized clinical trials demonstrating meaningful improvements in healthy adults? The answer is still not yet, which undeniably has been a noticeable theme throughout this entire peptide series. Excellent biology, encouraging early evidence, growing clinical experience, but human research that's still maturing. So now let's look at whether or not everyone should be trying to raise growth hormone, because by now you might be wondering if growth hormone is associated with recovery, muscle, and healthy aging, why wouldn't everyone want more of it? But growth hormone isn't simply a more is better hormone. Like many biological systems, there appears to be a healthy range. Too little can create problems, too much can also create problems. That's one reason these therapies should never be viewed as shortcuts. They're attempting to influence an extraordinarily complex biological system. And whenever we influence biology, there are almost always trade-offs to consider. So again, the goal isn't to maximize growth hormone, the goal is to support healthy physiology, and those aren't always the same thing. Okay, so far we've talked about CJC1295 with and without DAC and Ipamoralin, two therapies that are commonly paired together because they influence different parts of the body's natural growth hormone signaling pathways.

Sermorelin As A More Physiologic Option

Krista 24:05

But long before those peptides ever became popular, there was another therapy that many physicians viewed as a more physiologic alternative to injecting growth hormone itself, and that's SERMORIN. In many ways, SRMOLin helped establish the entire philosophy we've been discussing throughout today's episode. Instead of replacing growth hormone, could we encourage the body to release more of its own? Unlike CJC1295, which was designed in a laboratory to improve certain pharmacologic properties, SRMorilin is essentially a synthetic version of a portion of the body's own GHRH or that growth hormone-releasing hormone. Remember, GHRH is one of the signals your hypothalamus naturally sends to your pituitary gland. Its message is simple: release growth hormone. Sirmorin delivers essentially that same message. So conceptually, it's very similar to CJC 1295. The biggest difference isn't necessarily what they're trying to accomplish, it's how long they remain active in the body and how they've been developed and studied. One reason physicians prefer SRMOLin is familiarity. Surmorolin has been around longer than many of the newer growth hormone peptides, and physicians have years of clinical experience using it. It doesn't automatically make it better, but experience does matter. Another reason physicians tend to choose SRMOLin is philosophy. Some physicians prefer therapies that more closely resemble the body's own naturally occurring signaling molecules. Others prefer longer-acting peptides like CJC 1295 with DAC because they require fewer injections. Again, we're seeing another example where there isn't necessarily one universally correct answer: different physicians, different patients, different goals. And when we look at comparative data on SERMORIN versus CJC 1295 with DAC, we simply don't have good comparative outcomes data proving one strategy produces better long-term health outcomes. SERMORILIN has the longer clinical history and is shorter acting. So conceptually, it may resemble the body's native GHRH signaling more closely. CJC 1295 with DAC, on the other hand, has the pharmacologic advantage of much longer exposure and fewer injections, but that sustained exposure also means it's less like a brief natural GHRH pulse. And when we look at the research, like the other growth hormone secretagogues we've discussed, SRMORIN clearly stimulates growth hormone release. It also increases IgF-1 in many patients. Those findings are well supported. Where the questions become more sophisticated is in determining how much those hormonal changes translate into meaningful differences in body composition, strength, sleep, recovery, or healthy aging in otherwise healthy adults. Some studies are encouraging and the clinical experience is actually extensive, but once again, the large long-term human outcome data remain relatively limited. That doesn't mean SERMORIN doesn't work. It simply means we're still building the evidence. In simpler terms, imagine two teachers. One has been teaching for 30 years, one has only been teaching for five. Both may be excellent, both may produce wonderful students, but one has simply accumulated more years of experience. That's a little like where SERMORILIN sits today. It's one of the veterans of this category. That doesn't automatically make it the best, but it does mean physicians have had more time to understand how patients respond to it.

Tesamorelin And Visceral Fat Evidence

Krista 27:28

So now I'd like to introduce a peptide that tells a very different story, and that's tesamorilin. Unlike many of the peptides we've discussed throughout the series, tesamorin isn't simply popular in longevity medicine. It's actually an FDA-approved medication. That immediately raises an interesting question: approved for what? Certainly not for anti-aging, not for bodybuilding, not for longevity. Tesamorlin actually received FDA approval for the treatment of excess visceral abdominal fat in people living with HIV who developed a condition called HIV-associated lipodystrophy. Let's pause there for a second, because that approval tells us something really important. When the FDA approves a medication, it isn't saying this drug is good for anything and everything people think it might do. It's saying, based on the available evidence, we've concluded that the benefits outweigh the risks for this specific medical condition. Tesamorin was originally developed because people living with HIV began living much longer thanks to advances in antiviral therapy. But many developed this frustrating complication where fat began accumulating deep inside the abdomen around the internal organs. This isn't the fat that you can pinch under your skin. This is actually visceral fat. And unlike subcutaneous fat, visceral fat is metabolically active. It's associated with increased risk of cardiovascular disease, insulin resistance, type 2 diabetes, fatty liver disease, and chronic inflammation. Researchers wanted to know whether stimulating the body's own growth hormone system might reduce that specific type of fat. And clinical trials demonstrated that tesamoralin significantly reduced visceral fat in many patients with HIV-associated lipidystrophy. Those studies ultimately led to FDA approval. And naturally, people began asking if tesamoralin reduces visceral fat in patients with HIV, could it potentially help other populations struggling with excess visceral fat? And this is why longevity medicine has become so intrigued by it. It's an entirely reasonable scientific question, but as we're learning, a reasonable scientific question isn't the same thing as established evidence. So research is ongoing. Some early findings are actually encouraging, but we don't yet have the same level of evidence supporting its use for general longevity or age-related visceral fat as we do for the approved indication in HIV patients. So what about the brain health benefits? Because many of you have probably heard people discussing tesamorin in context with cognitive health. Where does that come from? Some researchers have actually explored whether improving growth hormone and IgF-1 signaling could influence certain aspects of brain function. There have been interesting early findings around this. The conversation comes primarily from a handful of studies, especially work led by researchers at the University of Washington and others, looking at adults with abdominal obesity and age-related cognitive concerns. They've reported signals suggesting possible improvements in executive functioning, so things like planning, organization, and decision making. They've also noticed improvements in some aspects of verbal memory, attention, and biomarkers associated with brain insulin signaling. One hypothesis is that increased growth hormone, increased IgF-1, reduced visceral fat, and improved insulin sensitivity may indirectly support brain function, which actually makes a lot of sense. So there's also interest in whether improving metabolic health reduces neuroinflammation. But these studies have generally been relatively small, relatively short, and not definitive. So while there have been some intriguing early studies suggesting possible improvements in certain aspects of memory and executive function, we're nowhere near being able to say that tesamorin should be reviewed as a treatment for cognitive decline. But this remains a developing area of research. It's intriguing and it's biologically plausible, but it's far from settled science. Again, one FDA approval tells us a therapy works for one specific condition. It doesn't automatically tell us it works for every condition that people hope it might. So up to this point, we've learned that every therapy has something in common. They're all peptides. They're all trying to influence your body's natural growth hormone signaling

MK-677 Benefits, Trade-Offs, And Risks

Krista 31:46

system. But our final therapy completely breaks that pattern. While it's a popular compound in longevity medicine and it's most commonly grouped in with growth hormone peptides, it's not actually a peptide at all. I'm talking about MK677, also known as I butamorin. If you spent any time researching peptides, you've almost certainly come across this one. MK677 is a small molecule drug, which sounds technical, and it should because it changes almost everything about how it behaves. It's always grouped in with peptides because its goal is remarkably similar. Like Ipamarelin, MK677 works through the ghrelin receptor. By activating that receptor, it encourages the pituitary gland to release more growth hormone, which can then increase IGF-1. So although MK677 isn't structurally a peptide, it's often discussed alongside them because it's trying to influence the same biological system. MK677 became so popular for several reasons. First, it's taken orally, no injections. For many people, that's actually very appealing. Second, clinical studies have shown that MK677 can increase growth hormone and IgF-1 levels. Researchers have also observed improvements in lean body mass in some studies. Sleep quality may improve for some individuals as well. Again, those findings are very interesting, but they don't tell the entire story because while every therapy has potential benefits, they also have potential downsides too. The question isn't whether one exists without the other. The question is whether the potential benefits outweigh the potential risks for the individuals sitting in front of you. With MK677, one of the biggest concerns involves appetite. Because it stimulates the ghrelin receptor, many people experience increased hunger. For someone struggling to gain weight, that may actually be beneficial. But for someone trying to lose weight, on the other hand, it can definitely become a challenge. Researchers have also observed increases in fasting blood glucose and insulin resistance in some individuals. It doesn't mean that everyone experiences these effects, but it does remind us that influencing one pathway often influences many others as well. Again, biology is rarely ever linear. It's kind of like adjusting the temperature in your home. You turn up the thermostat because you're cold and the living room warms up. That's great, but the upstairs bedrooms also become warmer and maybe even become intolerable. So does the kitchen, maybe the nursery. Changing one setting on that thermostat often affects multiple rooms in different ways. Your body's signaling pathways work much the same way. When we intentionally influence one hormone, we're often influencing many others at the same time. And that's why medicine is almost never as simple as increase this or decrease that. Everything is connected. But does MK677 build muscle? This is probably the biggest marketing claim that you'll see. And the honest answer is it depends on what you mean. Clinical studies have demonstrated increases in lean body mass, but lean body mass isn't necessarily the same thing as functional muscle. Lean body mass includes muscle, water, connective tissue, and other non-fat tissues. Some studies have demonstrated increases in lean body mass as measured by DEXA scans. But here's something important to think about. Lean body mass isn't exactly the same thing as muscle, as I just mentioned, and DEXA scans measure all of the body's non-fat tissues. So an increase in lean body mass by a DEXA doesn't necessarily tell us how much new functional muscle was actually built. And that's why most people don't care or maybe pay as much attention to what their DEXA scan says. They care whether they're healthier, stronger, moving better, and functioning better. And that's what we should always come back to. So what about longevity? Naturally, people have been asked whether increasing growth hormone in IGF-1 might actually slow aging. I'm obviously interested in that too, but the answer is complicated. Some evidence suggests improved body composition, better bone health, and improved quality of life in certain individuals. Other research raises important questions about chronically elevated IgF-1 signaling and potential relationships with certain cancers and aspects of aging, which is also an enormous concern for me and everything that we do at Panacea. I want to elaborate a little bit on the cancer scares because when I say that, I don't want people to hear HDH causes cancer. That's actually not what the evidence says at all. The concern is much more subtle, and here's the biology behind it: growth hormone increases IGF-1. IgF-1 promotes cell growth, cell division, and reduces apoptosis, which is that programmed cell death. Those are exactly the processes that you want during childhood, healing, and muscle repair. But those are also processes that cancer cells like. Scientists therefore asked if we chronically increase IgF-1, could we unintentionally stimulate the growth of microscopic cancers that already exist in the body? Notice what I did not say. I did not say it causes cancer. That's never been proven. The concern right now is theoretical and observational. Large epidemiological studies have found associations between higher circulating IGF-1 levels and increased risk of certain cancers, particularly breast, prostate, and colorectal cancers, but association does not equal causation. Many confounding factors exist. And studies of patients receiving medically supervised growth hormone replacement have generally not shown a clear increase in new cancers when appropriately prescribed, although monitoring is recommended, especially in people with a prior history of malignancy. And the FDA-approved tesamoralin label is very instructive when it comes to this. It contraindicates tesamoralin, an active malignancy, warns clinicians to weigh risks in people with prior malignancy, and explicitly states that the effects of prolonged IGF-1 elevation are unknown. That's very different, however, from proving that the therapy initiates cancer. So again, the science simply hasn't reached a definitive conclusion. Okay, at this point, after spending two episodes exploring the growth hormone system, you're probably asking, where do I personally stand? Honestly, I think these therapies represent another exciting chapter in regenerative medicine. And I think it's led to some genuinely innovative science. At the same time, I think enthusiasm once again moved a little faster than the evidence. The biology makes sense, the mechanisms are compelling. Many clinicians report encouraging outcomes, but many of the long-term questions we're asking today are still waiting to be answered. And that's okay. Science doesn't become stronger by pretending certainty exists where it doesn't, it becomes stronger by continuing to ask better questions. And that's exactly what I hope we're doing together throughout this series. Remember, innovation begins with curiosity. Wisdom comes from asking whether the evidence has caught up.

Promise Versus Proof Scorecard

Krista 38:43

All right, it's time. Let's see where today's therapies land on our promise versus proof scale. When we look at CJC 1295, I'm giving the biological foundation a rating of nine out of 10. The preclinical evidence, I'm giving an eight and a half, but the human clinical evidence is only at a four. When it comes to clinical experience, I'm rating it at a seven, and the long-term safety evidence, I'm rating at a three. So overall, I'm giving CJC 1295 a 6.5 out of 10. When we look at IPamorelin, I'm giving the biological foundation eight and a half, the preclinical evidence an eight, the human clinical evidence a three and a half, the clinical experience a seven, and the long-term safety evidence a three. So overall, my clinical confidence in IPAMRelin is at a six. When we look at SERMORLin, this one gets a seven out of ten for me. It's biological foundation, preclinical evidence, and clinical experience are all in the eight, in my opinion. And while the human clinical evidence and long-term safety evidence is stronger than CJC 1295 and IPAMRLin, there's still some work to do in this area. So I'm scoring those at a five for an overall seven rating. Tesamorlin, however, gets an eight out of 10 when we're referring to its FDA indication for HIV-associated lipodystrophy. The biological foundation is at a nine, preclinical evidence at a nine, human clinical evidence at an eight, again, for its approved indication, clinical experience at an eight and a half, and its long-term safety evidence at a seven. So again, my overall clinical confidence score is going to be an eight out of 10 for Tesamorlin when we're talking about its approved FDA indication for HIV associated lipodystrophy. But if I were to score it based on its general longevity and anti-aging uses, I would probably give it closer to a five or a six. When it comes to MK677 or Ibutamorin, I'm rating this one at a six. Similarly to Surmorlin, its biological foundation and preclinical evidence are in the eights, in my opinion, but the clinical evidence lags a bit at a seven rating. And while the human clinical evidence is also at a five, there's still a lot to learn about the long-term safety of this peptide. So in this category, I'm giving it a three for an overall rating of six. Okay, so if there's one lesson I hope you carry with you after these two episodes, it's this. Not every therapy that increases growth hormone is doing the same thing. And not every promising biological mechanism ultimately translates into better long-term health. The goal isn't simply to increase growth hormone. The goal is to improve your health. And by now, I hope you understand that those aren't always the same thing, which probably leaves you wondering, should I take any of these? And my answer is that's the wrong first question that you should be asking. The first question is, do you have a reason to believe your growth hormone system needs support? The second question is, what are you trying to accomplish? And the third question is, do the potential benefits outweigh the potential risks for you? Those answers are going to be very different for a 32-year-old professional athlete, a 50-year-old woman recovering from surgery, a 70-year-old man with age-related loss of muscle mass, and someone with a personal history of cancer.

Next Week Brain Peptides Plus Disclaimer

Krista 42:03

So as we wrap up today's episode, I want to say that if all of this was not enough to get your brain reeling around this contagious excitement about peptides, my next episode definitely will. So be sure to tune in next week because we'll be exploring the category of brain peptides, including CMAX, C link, dihexa, cerebral lysin, and several other fascinating compounds being investigated for memory, focus, mood, recovery after brain injury, and neurodegenerative disease. And we'll ask an important question: can we really influence the brain the same way we're trying to influence healing or growth hormone? Or is the science telling a very different story? And as we close out today's episode, please remember that everything shared on Serenity and Fire is meant for general education and inspiration purposes only. The topics we discuss are not intended to diagnose, treat, or replace personalized medical care. So please always consult with your healthcare provider regarding your individual health concerns, laboratory results, medications, and treatment decisions before taking anything we talk about on the show. Your health is unique and your care should be too. Okay, that's it for today's episode. Thank you so much for listening to Serenity and Fire. If today's episode helped you better understand the difference between growth hormone replacement and growth hormone optimization and gave you greater confidence in evaluating the rapidly evolving world of growth hormone peptides, definitely support the show. The best way to do that is to follow, leave a review, and share this episode with those you love most. Together, we can empower more people to make informed, evidence-informed decisions about their health. Until next time, honor your biology, choose your therapies with intention, let wisdom grow alongside curiosity, and keep balancing serenity with fire. I'm Krista Guigeni and I'll talk with you more in our next episode.

Spa Offer And Serenity10 Code

Krista 43:54

At Pennusy of Luxury Spa Boutique, we don't just offer traditional spa treatments. We create rituals that relax your mind, restore your health, and rejuvenate your spirit. From biohacking technologies to advanced oncology trained care, everything we do is designed to help you heal on the deepest level with clean, holistic therapies, products, and amenities that are second to none. And right now you can experience two of my favorites, our whole body LED lightbed or hyperbolic oxygen therapies. And as a thank you for listening, you'll get 10% off your first session when you use the code Serenity10 at Booking. What is your panacea? Let us help you find it because true wellness isn't a quick fix, it's a ritual.